 Sandra Luna-Fineman
Concepts (288)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinoblastoma | 9 | 2023 | 40 | 3.060 |
Why?
| | Retinal Neoplasms | 7 | 2023 | 36 | 2.560 |
Why?
| | Hodgkin Disease | 6 | 2023 | 157 | 2.120 |
Why?
| | Wilms Tumor | 4 | 2025 | 87 | 1.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 9 | 2025 | 1787 | 1.040 |
Why?
| | Neoplasms | 18 | 2024 | 2741 | 1.000 |
Why?
| | Child | 43 | 2025 | 22308 | 0.630 |
Why?
| | Eye Enucleation | 1 | 2019 | 15 | 0.630 |
Why?
| | Vincristine | 4 | 2023 | 131 | 0.630 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2021 | 98 | 0.620 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2019 | 286 | 0.600 |
Why?
| | Developing Countries | 8 | 2025 | 317 | 0.560 |
Why?
| | Kidney Neoplasms | 4 | 2025 | 405 | 0.560 |
Why?
| | Guatemala | 9 | 2024 | 347 | 0.560 |
Why?
| | Medical Oncology | 6 | 2024 | 316 | 0.540 |
Why?
| | Time-to-Treatment | 1 | 2019 | 217 | 0.540 |
Why?
| | Refusal to Treat | 1 | 2017 | 16 | 0.530 |
Why?
| | Burkitt Lymphoma | 1 | 2017 | 63 | 0.510 |
Why?
| | Child, Preschool | 25 | 2025 | 11457 | 0.500 |
Why?
| | Neoadjuvant Therapy | 1 | 2019 | 419 | 0.500 |
Why?
| | Malnutrition | 1 | 2017 | 85 | 0.480 |
Why?
| | Etoposide | 5 | 2023 | 163 | 0.480 |
Why?
| | Carboplatin | 4 | 2023 | 146 | 0.450 |
Why?
| | Antineoplastic Agents | 3 | 2023 | 2166 | 0.450 |
Why?
| | Cyclophosphamide | 4 | 2023 | 256 | 0.440 |
Why?
| | Survival Rate | 9 | 2025 | 1970 | 0.400 |
Why?
| | Infant | 17 | 2025 | 9818 | 0.390 |
Why?
| | Doxorubicin | 3 | 2023 | 358 | 0.370 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2017 | 646 | 0.370 |
Why?
| | Sarcoma, Ewing | 2 | 2025 | 100 | 0.360 |
Why?
| | Neoplasm Staging | 7 | 2019 | 1398 | 0.360 |
Why?
| | Eye Neoplasms | 1 | 2011 | 28 | 0.360 |
Why?
| | Lymphoma, Follicular | 4 | 2016 | 53 | 0.350 |
Why?
| | Adolescent | 27 | 2025 | 22007 | 0.330 |
Why?
| | Positron-Emission Tomography | 3 | 2017 | 310 | 0.320 |
Why?
| | Bone Neoplasms | 2 | 2025 | 253 | 0.310 |
Why?
| | Humans | 54 | 2025 | 141187 | 0.290 |
Why?
| | Contrast Media | 4 | 2018 | 470 | 0.290 |
Why?
| | Biomarkers, Tumor | 5 | 2025 | 1251 | 0.280 |
Why?
| | Male | 33 | 2025 | 69783 | 0.280 |
Why?
| | Practice Guidelines as Topic | 3 | 2025 | 1597 | 0.270 |
Why?
| | Female | 35 | 2025 | 75515 | 0.270 |
Why?
| | Germ-Line Mutation | 2 | 2022 | 167 | 0.270 |
Why?
| | Magnetic Resonance Imaging | 7 | 2018 | 3709 | 0.260 |
Why?
| | Gadolinium | 2 | 2018 | 81 | 0.250 |
Why?
| | Central America | 2 | 2019 | 24 | 0.250 |
Why?
| | Hematology | 2 | 2024 | 19 | 0.230 |
Why?
| | Disease-Free Survival | 3 | 2021 | 715 | 0.230 |
Why?
| | Myelodysplastic Syndromes | 2 | 1999 | 142 | 0.230 |
Why?
| | Genetic Heterogeneity | 1 | 2025 | 58 | 0.230 |
Why?
| | Prognosis | 9 | 2025 | 4073 | 0.230 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 374 | 0.230 |
Why?
| | Coronavirus Infections | 2 | 2020 | 371 | 0.220 |
Why?
| | Clonal Evolution | 1 | 2025 | 44 | 0.220 |
Why?
| | Nephrectomy | 1 | 2025 | 157 | 0.220 |
Why?
| | Pediatrics | 5 | 2024 | 1094 | 0.210 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2015 | 147 | 0.210 |
Why?
| | Tumor Microenvironment | 3 | 2025 | 692 | 0.200 |
Why?
| | Multimodal Imaging | 4 | 2018 | 120 | 0.200 |
Why?
| | Infant, Newborn | 8 | 2021 | 6275 | 0.190 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 338 | 0.180 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2021 | 1073 | 0.180 |
Why?
| | Lymphatic Irradiation | 1 | 2021 | 10 | 0.180 |
Why?
| | Libraries, Medical | 1 | 2021 | 12 | 0.170 |
Why?
| | RNA, Neoplasm | 1 | 2021 | 79 | 0.170 |
Why?
| | Treatment Refusal | 2 | 2019 | 96 | 0.170 |
Why?
| | Circulating Tumor DNA | 1 | 2021 | 35 | 0.170 |
Why?
| | Prospective Studies | 6 | 2023 | 7739 | 0.170 |
Why?
| | Disease Management | 2 | 2020 | 633 | 0.170 |
Why?
| | Pandemics | 4 | 2022 | 1653 | 0.170 |
Why?
| | Fellowships and Scholarships | 1 | 2024 | 319 | 0.160 |
Why?
| | DNA Replication | 1 | 2022 | 240 | 0.160 |
Why?
| | Herpesvirus 4, Human | 1 | 2021 | 165 | 0.160 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2019 | 378 | 0.160 |
Why?
| | Ferrosoferric Oxide | 2 | 2018 | 24 | 0.160 |
Why?
| | DNA Repair | 1 | 2022 | 234 | 0.160 |
Why?
| | B7-H1 Antigen | 1 | 2022 | 221 | 0.160 |
Why?
| | Chemoradiotherapy | 1 | 2021 | 232 | 0.150 |
Why?
| | Chromosomes, Human, Pair 7 | 2 | 1999 | 17 | 0.150 |
Why?
| | Monosomy | 2 | 1999 | 12 | 0.150 |
Why?
| | Myeloproliferative Disorders | 1 | 1999 | 27 | 0.150 |
Why?
| | Retrospective Studies | 9 | 2025 | 16273 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2023 | 1018 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 192 | 0.150 |
Why?
| | Information Dissemination | 1 | 2021 | 224 | 0.150 |
Why?
| | Chromosome Aberrations | 2 | 1999 | 160 | 0.140 |
Why?
| | Leukemia | 2 | 2017 | 244 | 0.140 |
Why?
| | Fractures, Spontaneous | 1 | 2017 | 16 | 0.140 |
Why?
| | Bone Marrow Diseases | 1 | 2017 | 20 | 0.140 |
Why?
| | Nicaragua | 1 | 2017 | 7 | 0.130 |
Why?
| | Disease Progression | 3 | 2021 | 2793 | 0.130 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 1997 | 36 | 0.130 |
Why?
| | Orbital Diseases | 1 | 1997 | 34 | 0.130 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2018 | 109 | 0.130 |
Why?
| | Osteonecrosis | 1 | 2017 | 24 | 0.130 |
Why?
| | Biopsy, Needle | 1 | 1997 | 187 | 0.130 |
Why?
| | Delivery of Health Care | 2 | 2021 | 961 | 0.130 |
Why?
| | Bone Diseases | 1 | 2017 | 66 | 0.130 |
Why?
| | DNA Mutational Analysis | 2 | 2016 | 398 | 0.130 |
Why?
| | Edema | 1 | 2017 | 131 | 0.130 |
Why?
| | Lymphoma | 1 | 2018 | 228 | 0.130 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 1 | 2016 | 17 | 0.120 |
Why?
| | Risk Factors | 6 | 2021 | 10438 | 0.120 |
Why?
| | Brain Diseases | 1 | 2017 | 149 | 0.120 |
Why?
| | Morbidity | 1 | 2017 | 322 | 0.120 |
Why?
| | Income | 2 | 2023 | 201 | 0.120 |
Why?
| | Bone Marrow | 1 | 2017 | 302 | 0.120 |
Why?
| | Sarcoma | 1 | 2018 | 190 | 0.120 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 286 | 0.120 |
Why?
| | Treatment Outcome | 6 | 2023 | 11120 | 0.120 |
Why?
| | Chelating Agents | 1 | 2015 | 74 | 0.120 |
Why?
| | Aftercare | 1 | 2017 | 218 | 0.110 |
Why?
| | LIM Domain Proteins | 1 | 2015 | 20 | 0.110 |
Why?
| | Leukemia, Myeloid | 1 | 1995 | 47 | 0.110 |
Why?
| | Myeloablative Agonists | 1 | 2014 | 23 | 0.110 |
Why?
| | Chromosome Deletion | 1 | 1995 | 118 | 0.110 |
Why?
| | Indians, Central American | 1 | 2014 | 6 | 0.110 |
Why?
| | Gamma Rays | 1 | 2014 | 57 | 0.110 |
Why?
| | INDEL Mutation | 1 | 2014 | 17 | 0.110 |
Why?
| | Lymphoma, B-Cell | 2 | 1992 | 130 | 0.110 |
Why?
| | Young Adult | 10 | 2022 | 13673 | 0.110 |
Why?
| | Central Venous Catheters | 1 | 2014 | 51 | 0.110 |
Why?
| | Whole Body Imaging | 1 | 2014 | 26 | 0.110 |
Why?
| | Retinoblastoma Protein | 1 | 2014 | 59 | 0.110 |
Why?
| | Receptors, Complement 3d | 1 | 2015 | 140 | 0.110 |
Why?
| | Combined Modality Therapy | 3 | 2013 | 1243 | 0.110 |
Why?
| | Heart Diseases | 1 | 2017 | 335 | 0.110 |
Why?
| | Neutropenia | 1 | 2014 | 157 | 0.100 |
Why?
| | Latin America | 3 | 2022 | 91 | 0.100 |
Why?
| | Transplantation, Autologous | 1 | 2014 | 280 | 0.100 |
Why?
| | Immunoglobulin M | 1 | 2015 | 287 | 0.100 |
Why?
| | Transplantation Conditioning | 1 | 2014 | 184 | 0.100 |
Why?
| | Point Mutation | 1 | 2014 | 237 | 0.100 |
Why?
| | Radiopharmaceuticals | 1 | 2014 | 188 | 0.100 |
Why?
| | Fever | 1 | 2014 | 308 | 0.100 |
Why?
| | Glucocorticoids | 1 | 2017 | 533 | 0.100 |
Why?
| | Follow-Up Studies | 2 | 2025 | 5200 | 0.100 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2014 | 155 | 0.100 |
Why?
| | Down Syndrome | 1 | 2019 | 506 | 0.090 |
Why?
| | Bacterial Infections | 1 | 2014 | 245 | 0.090 |
Why?
| | Cerebellar Neoplasms | 1 | 2014 | 179 | 0.090 |
Why?
| | Patient Safety | 1 | 2016 | 335 | 0.090 |
Why?
| | Medulloblastoma | 1 | 2014 | 218 | 0.090 |
Why?
| | Bacteremia | 1 | 2014 | 216 | 0.090 |
Why?
| | Time Factors | 2 | 2021 | 6956 | 0.090 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 1992 | 174 | 0.090 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2015 | 429 | 0.090 |
Why?
| | Major Histocompatibility Complex | 1 | 1992 | 234 | 0.090 |
Why?
| | Neoplasm Proteins | 1 | 2015 | 432 | 0.090 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2132 | 0.090 |
Why?
| | Proto-Oncogene Proteins | 1 | 2015 | 623 | 0.090 |
Why?
| | Adult | 10 | 2022 | 39177 | 0.090 |
Why?
| | Crohn Disease | 1 | 2014 | 254 | 0.080 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1261 | 0.080 |
Why?
| | Incidence | 2 | 2014 | 2794 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 3 | 2018 | 2746 | 0.080 |
Why?
| | Macrophages | 1 | 2018 | 1561 | 0.080 |
Why?
| | Dura Mater | 1 | 2009 | 34 | 0.080 |
Why?
| | Promoter Regions, Genetic | 1 | 2014 | 1242 | 0.080 |
Why?
| | DNA Methylation | 1 | 2014 | 645 | 0.070 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2008 | 11 | 0.070 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2008 | 21 | 0.070 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2009 | 89 | 0.070 |
Why?
| | Community-Institutional Relations | 1 | 2009 | 101 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 852 | 0.070 |
Why?
| | Neuroblastoma | 1 | 2009 | 163 | 0.070 |
Why?
| | Meningeal Neoplasms | 1 | 2009 | 103 | 0.070 |
Why?
| | Survival Analysis | 3 | 2022 | 1319 | 0.070 |
Why?
| | Idarubicin | 1 | 2007 | 5 | 0.070 |
Why?
| | Vidarabine | 1 | 2007 | 35 | 0.070 |
Why?
| | Soft Tissue Neoplasms | 1 | 2008 | 119 | 0.070 |
Why?
| | Healthcare Disparities | 1 | 2014 | 666 | 0.070 |
Why?
| | Betacoronavirus | 2 | 2020 | 276 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 1990 | 501 | 0.060 |
Why?
| | Interleukin-2 | 1 | 2007 | 453 | 0.060 |
Why?
| | Virus Shedding | 1 | 2006 | 48 | 0.060 |
Why?
| | Poliovirus | 1 | 2006 | 85 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2022 | 5636 | 0.060 |
Why?
| | Mutation | 1 | 2016 | 4013 | 0.060 |
Why?
| | Health Services Accessibility | 1 | 2013 | 1016 | 0.060 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2025 | 76 | 0.050 |
Why?
| | Societies, Medical | 2 | 2020 | 855 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2014 | 1865 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 450 | 0.050 |
Why?
| | Suspensions | 1 | 2022 | 29 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2017 | 1973 | 0.040 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2021 | 24 | 0.040 |
Why?
| | RNA-Binding Protein EWS | 1 | 2021 | 26 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2021 | 3348 | 0.040 |
Why?
| | United States | 2 | 2023 | 15220 | 0.040 |
Why?
| | Cancer Care Facilities | 2 | 2014 | 43 | 0.040 |
Why?
| | India | 1 | 2021 | 208 | 0.040 |
Why?
| | Translocation, Genetic | 1 | 2021 | 109 | 0.040 |
Why?
| | Remission Induction | 2 | 2009 | 309 | 0.040 |
Why?
| | Health Resources | 1 | 2021 | 129 | 0.040 |
Why?
| | Transcriptional Regulator ERG | 1 | 2019 | 17 | 0.040 |
Why?
| | Radiation Dosage | 1 | 2021 | 191 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 204 | 0.040 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2019 | 42 | 0.040 |
Why?
| | Fetal Hemoglobin | 1 | 1999 | 7 | 0.040 |
Why?
| | Withholding Treatment | 2 | 2011 | 78 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2025 | 1431 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2019 | 194 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2363 | 0.040 |
Why?
| | Vietnam | 1 | 2018 | 27 | 0.040 |
Why?
| | Rwanda | 1 | 2018 | 32 | 0.040 |
Why?
| | Health Care Surveys | 1 | 2020 | 565 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1764 | 0.030 |
Why?
| | Risk Assessment | 2 | 2021 | 3490 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2021 | 1056 | 0.030 |
Why?
| | Histiocytes | 1 | 1997 | 7 | 0.030 |
Why?
| | California | 1 | 2019 | 462 | 0.030 |
Why?
| | S100 Proteins | 1 | 1997 | 37 | 0.030 |
Why?
| | Haplotypes | 1 | 2019 | 496 | 0.030 |
Why?
| | Antigens, CD1 | 1 | 1997 | 58 | 0.030 |
Why?
| | Systems Integration | 1 | 2017 | 38 | 0.030 |
Why?
| | Gene Deletion | 1 | 1999 | 388 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 1997 | 209 | 0.030 |
Why?
| | Registries | 2 | 2021 | 2135 | 0.030 |
Why?
| | Orbit | 1 | 1997 | 71 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 704 | 0.030 |
Why?
| | Observer Variation | 1 | 2017 | 355 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1662 | 0.030 |
Why?
| | Leukemia, Radiation-Induced | 1 | 1995 | 4 | 0.030 |
Why?
| | Genes, Neurofibromatosis 1 | 1 | 1995 | 4 | 0.030 |
Why?
| | Femur | 1 | 2017 | 260 | 0.030 |
Why?
| | Genes, ras | 1 | 1995 | 95 | 0.030 |
Why?
| | Chromosome Disorders | 1 | 1995 | 43 | 0.030 |
Why?
| | Genetic Diseases, Inborn | 1 | 1995 | 46 | 0.030 |
Why?
| | Carmustine | 1 | 2014 | 53 | 0.030 |
Why?
| | Germinal Center | 1 | 2015 | 66 | 0.030 |
Why?
| | Adalimumab | 1 | 2014 | 55 | 0.030 |
Why?
| | Microfilament Proteins | 1 | 2015 | 132 | 0.030 |
Why?
| | Neoplasms, Second Primary | 1 | 1995 | 109 | 0.030 |
Why?
| | Tumor Cells, Cultured | 2 | 1992 | 959 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2014 | 294 | 0.030 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1992 | 38 | 0.020 |
Why?
| | Transcription Factors | 1 | 2021 | 1703 | 0.020 |
Why?
| | CD8 Antigens | 1 | 1992 | 75 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2019 | 1402 | 0.020 |
Why?
| | Cancer Survivors | 1 | 2017 | 297 | 0.020 |
Why?
| | Risk | 1 | 1995 | 904 | 0.020 |
Why?
| | CD3 Complex | 1 | 1992 | 106 | 0.020 |
Why?
| | Graft vs Host Disease | 1 | 2014 | 254 | 0.020 |
Why?
| | Interleukin-3 | 1 | 1992 | 24 | 0.020 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2015 | 464 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 1995 | 411 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3588 | 0.020 |
Why?
| | Recurrence | 1 | 2014 | 1110 | 0.020 |
Why?
| | HIV Infections | 1 | 2006 | 3017 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2014 | 482 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 1992 | 335 | 0.020 |
Why?
| | Tumor Lysis Syndrome | 1 | 1990 | 8 | 0.020 |
Why?
| | Cell Communication | 1 | 1992 | 318 | 0.020 |
Why?
| | Treatment Failure | 1 | 2011 | 354 | 0.020 |
Why?
| | Waardenburg Syndrome | 1 | 2009 | 1 | 0.020 |
Why?
| | Microphthalmia-Associated Transcription Factor | 1 | 2009 | 14 | 0.020 |
Why?
| | Adrenalectomy | 1 | 2009 | 69 | 0.020 |
Why?
| | El Salvador | 1 | 2009 | 6 | 0.020 |
Why?
| | Congresses as Topic | 1 | 2011 | 230 | 0.020 |
Why?
| | Honduras | 1 | 2009 | 10 | 0.020 |
Why?
| | Oncology Service, Hospital | 1 | 2009 | 15 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2015 | 858 | 0.020 |
Why?
| | Neural Crest | 1 | 2009 | 121 | 0.020 |
Why?
| | Mexico | 1 | 2009 | 232 | 0.020 |
Why?
| | Pulmonary Veins | 1 | 2009 | 106 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2009 | 244 | 0.020 |
Why?
| | Cell Lineage | 1 | 2009 | 350 | 0.020 |
Why?
| | Immunotherapy | 1 | 1992 | 640 | 0.020 |
Why?
| | Program Development | 1 | 2009 | 368 | 0.020 |
Why?
| | Italy | 1 | 2007 | 111 | 0.020 |
Why?
| | Information Services | 1 | 2007 | 49 | 0.020 |
Why?
| | Nutrition Assessment | 1 | 2007 | 93 | 0.020 |
Why?
| | International Cooperation | 1 | 2007 | 203 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 1992 | 1448 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2018 | 2560 | 0.010 |
Why?
| | Cooperative Behavior | 1 | 2007 | 462 | 0.010 |
Why?
| | Terminal Care | 1 | 2007 | 251 | 0.010 |
Why?
| | Feces | 1 | 2006 | 504 | 0.010 |
Why?
| | Skin Neoplasms | 1 | 2009 | 849 | 0.010 |
Why?
| | Aged | 1 | 2018 | 24574 | 0.010 |
Why?
| | Middle Aged | 1 | 2018 | 34434 | 0.010 |
Why?
| | Quality of Life | 1 | 2007 | 2999 | 0.010 |
Why?
| | Receptors, Interleukin-3 | 1 | 1992 | 5 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 1 | 1992 | 386 | 0.010 |
Why?
| | Cell Division | 1 | 1992 | 798 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1992 | 1357 | 0.000 |
Why?
| | Lymphocyte Activation | 1 | 1992 | 1150 | 0.000 |
Why?
|
|
Luna-Fineman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|